• DMH1: Precision ALK2 Inhibitor for Organoid and Cancer Resea

  2026-07-26

  DMH1, a selective ALK2 inhibitor, is redefining experimental control in organoid and non-small cell lung cancer studies by enabling tunable, pathway-specific modulation. Its reliable inhibition of BMP signaling supports high-efficiency organoid formation and innovative disease models, while minimizing off-target effects.

• Radioiodinated Balsalazide: A Selective Radiotracer for Ulce

  2026-07-25

  This study presents the development and bioevaluation of [125/131I]balsalazide as a highly selective radiotracer for imaging ulcerative colitis (UC) in mice. The innovation lies in achieving high radiochemical purity and target organ retention, enabling prolonged and specific detection of UC lesions, which addresses key limitations in previous diagnostic approaches.

• U-73122: A Potent Phospholipase C Inhibitor for Signal Modul

  2026-07-24

  U-73122 stands out as a precision tool for dissecting PLC signaling, empowering researchers to unravel calcium flux and chemotaxis in disease models. With robust protocol guidance and troubleshooting strategies, this phospholipase C inhibitor from APExBIO enables reproducible and insightful studies in cellular signaling and inflammation research.

• Thymosin-β4 Promotes Angiogenesis in CLI via Notch/NF-κB Pat

  2026-07-24

  Lv et al. demonstrated that thymosin-β4 enhances angiogenesis in a mouse model of critical limb ischemia by activating both Notch and NF-κB signaling. Their mechanistic and functional analyses reveal how pathway-specific inhibition modulates this effect, offering new perspectives for vascular regeneration research.

• CLCC1 Identified as Key Host Factor in Herpesvirus Nuclear E

  2026-07-23

  A recent study reveals CLCC1 as a crucial host protein mediating membrane fusion during herpesvirus nuclear egress, resolving a major unknown in the herpesvirus life cycle. This insight not only advances fundamental virology but also suggests new targets for antiviral strategies and immunomodulatory interventions.

• Erastin as a Ferroptosis Inducer: Workflows and Troubleshoot

  2026-07-23

  Erastin stands out as a precision ferroptosis inducer for dissecting oxidative cell death in RAS- and BRAF-mutant cancer models. This article delivers actionable protocols, advanced assay tips, and practical troubleshooting to help you maximize experimental reproducibility and biological insight with Erastin from APExBIO.

• Prion-Induced Mutagenesis Enables Adaptive Genome Diversific

  2026-07-22

  This study uncovers how prion-based protein self-assembly in yeast drives heritable and reversible increases in mutagenesis, facilitating rapid adaptation under stress. The findings reshape our understanding of epigenetic mechanisms controlling genome stability, with broad implications for drug resistance and evolutionary dynamics.

• 4-Methylumbelliferyl-β-D-Glucopyranoside: Next-Gen Assay Pre

  2026-07-22

  Discover how 4-Methylumbelliferyl-β-D-Glucopyranoside (4-MUG) is redefining β-glucosidase activity assays. This in-depth review explores advanced assay design, unique insights from recent mRNA therapy research, and actionable parameters for robust lysosomal enzyme studies.

• PXR Activation Promotes Liver Regeneration and CYP Induction

  2026-07-21

  Activation of the pregnane X receptor (PXR) in rats leads to simultaneous liver enlargement, regeneration, and robust upregulation of CYP3A1/2 and CYP2C6/11 metabolic enzymes. This work clarifies how molecular signaling through PXR coordinates both hepatic growth and enhanced metabolic capacity, with implications for liver disease models and drug metabolism studies.

• Copper-Coordinated Nanoassemblies Enable Cuproptosis for Can

  2026-07-21

  This study introduces a baicalein–copper nanoassembly integrating chemodynamic and photodynamic modalities to induce cuproptosis, a copper-triggered regulated cell death, for cancer therapy. The platform demonstrates bone-penetrating capability, precise tumor targeting, and robust generation of highly reactive oxygen species, offering a promising strategy for overcoming major limitations in current cancer treatments.

• Bile Acid Retention Disrupts Tumor Antigenicity in MASH-HCC

  2026-07-20

  This study uncovers how bile acid retention in MASH-associated hepatocellular carcinoma (MASH-HCC) impairs tumor antigen presentation by disrupting the NLRC5-MHC-I axis, leading to immune evasion. Targeting bile acid metabolism restores antigenicity and enhances immunotherapy response, offering a mechanistic foundation for overcoming resistance in metabolically driven liver cancer.

• Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Pract

  2026-07-20

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) is designed to prevent unwanted protein degradation during extraction and analysis, especially in workflows where EDTA would interfere with downstream assays such as phosphorylation detection. It is not suitable for protocols requiring metalloprotease inhibition or applications incompatible with DMSO.

• ECL Western Blotting Substrate: Protocol and Technical Guide

  2026-07-19

  ECL Western Blotting Substrate (SKU K2187) provides a sensitive, nonradioactive solution for the chemiluminescent detection of HRP-conjugated proteins in Western blot assays. It is suited for workflows in molecular biology, cancer biology, and signal transduction pathway research where clear signal and reprobing are required. This product should not be used for fluorescent or radioactive detection methods.

• PPM-18: Next-Generation iNOS Inhibition for Translational Im

  2026-07-18

  Explore the advanced mechanism and translational potential of PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide) as a selective iNOS expression inhibitor. This article uniquely bridges NF-κB pathway biology with practical protocol design in inflammation and sepsis research.

• Structural Diversity of Full-Length Human αvβ3 Integrin by C

  2026-07-17

  This study presents high-resolution cryo-EM structures of full-length human integrin αvβ3, identifying five previously uncharacterized intermediate conformations and revealing a continuum of activation states. These findings provide critical structural insights that can inform the rational design of next-generation integrin inhibitors with improved specificity.

450 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page